Our Strategy...


Proximagen's objective is to become one of the world's leading companies developing therapeutics for patients suffering from diseases of the CNS, neuroinflammation, inflammation and oncology.

Please click here to read Proximagen's strategy



Our Pipeline...


Our passion for advancing innovation is evident in the breadth and depth of our pipeline. Visit our pipeline.


When promising partnership opportunities arise, Proximagen can move quickly.


Proximagen is an entrepreneurial company. Therefore, we feel a strong sense of urgency to act decisively with each opportunity, focusing development efforts on programmes showing the most visible commercialisation opportunities.



We are interested in:


  • Novel small molecules
  • Targets with a pre-clinical or clinical proof of concept
  • Technologies with strong patent protection



Areas of interest for in-licensing partnerships:


  • Parkinson’s disease
  • Alzheimer’s disease/Cognition
  • Epilepsy
  • Neuroinflammation/inflammation
  • Neuro-oncology



Proximagen considers opportunities at all stages of development, even at very early stages of development or programmes that are in the later stages of clinical development. The Proximagen business development team understands the importance of science and business in each partnership and we are interested in reviewing opportunities which match our strategic focus. We will work with you closely throughout the partnering process to create deals which add value for mutual success.